弥散磁共振成像限制谱成像在胶质母细胞瘤瘤周脑区表征中的诊断价值:总生存期与无进展生存期分析
本研究纳入42例未经治疗的IDH野生型胶质母细胞瘤患者,采用限制谱成像(RSI)评估肿瘤不同区域的细胞密度,并与FA、MD等传统弥散指标比较预后价值。结果显示RSI细胞密度指数在对比增强肿瘤核心最高,并向瘤周区梯度下降,预测准确率81%(P<0.001);较高的RSI细胞密度指数与较短的总生存期显著相关(肿瘤核心HR 3.6,95%CI 1.3-9.5,P=0.002),瘤周强化区亦一致(HR 3.6,95%CI 1.0-12.3,P=0.041)。RSI、FA、MD与MGMT启动子甲基化状态均无统计学显著差异。
要点
- RSI细胞密度指数在对比增强肿瘤核心最高,向瘤周区呈梯度下降,预测准确率81%(P<0.001)。
- 对比增强肿瘤核心RSI细胞密度指数较高与总生存期较短显著相关(HR 3.6,95%CI 1.3-9.5,P=0.002)。
- 瘤周强化区RSI细胞密度指数较高亦与总生存期较短相关(HR 3.6,95%CI 1.0-12.3,P=0.041)。
关键影像表现/征象
- RSI细胞密度指数在对比增强肿瘤核心最高,从肿瘤核心向瘤周区边缘呈负梯度。
- 对比增强肿瘤核心RSI细胞密度指数较高与总生存期较短显著相关(HR 3.6,95%CI 1.3-9.5,P=0.002),同时MD降低(HR 0.31,95%CI 0.1-0.8,P=0.008)。
- 瘤周强化区RSI细胞密度指数较高亦与总生存期较短相关(HR 3.6,95%CI 1.0-12.3,P=0.041)。
- RSI细胞密度指数、FA和MD与MGMT启动子甲基化状态之间无统计学显著差异。
诊断标准与关键数值
- RSI细胞密度指数从肿瘤核心至瘤周区边缘呈梯度下降,预测准确率81%(P<0.001)。
- 对比增强肿瘤核心:RSI细胞密度指数较高与总生存期较短相关(HR 3.6,95%CI 1.3-9.5,P=0.002),MD降低与总生存期较短相关(HR 0.31,95%CI 0.1-0.8,P=0.008)。
- 瘤周强化区:RSI细胞密度指数较高与总生存期较短相关(HR 3.6,95%CI 1.0-12.3,P=0.041)。
临床应用与阅片要点
- 作者认为RSI细胞密度指数可能作为预后生物标志物,用于改善胶质母细胞瘤患者的风险分层。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: We studied the ability of Restriction Spectrum Imaging (RSI), a novel advanced diffusion imaging technique, to estimate levels of cellularity in different glioblastoma regions, evaluated their prognostic value compared with established clinical diffusion metrics such as fractional anisotropy (FA) and mean diffusivity (MD).
METHODS: Forty-two patients with untreated glioblastoma, IDH-wildtype, were examined with an advanced MRI tumor protocol. The region of interest (ROI) was obtained from the contrast-enhancing part of tumor and the peritumoral brain zones and then co-registered with RSI-cellularity index, FA and MD maps. Histogram parameters of diffusion metrics were assessed for all ROI locations and compared to MGMT promoter methylation status and survival. The ability of RSI-cellularity index, FA, and MD to stratify survival and were assessed by Cox proportional hazard regression, adjusted for significant clinical predictors.
RESULTS: The highest RSI-cellularity index was measured in contrast-enhancing tumor core with a negative gradient from tumor core to the periphery of peritumoral zone with predictive accuracy 81 % (P < 0.001). Shorter overall survival was significant associated with higher RSI-cellularity index (hazard ratio (HR) 3.6, 95 % confidence interval (CI) 1.3-9.5, P = 0.002) with synchronal decrease in MD (HR 0.31, 95 %CI 0.1-0.8, P = 0.008) in the contrast-enhanced tumor core. This association was also consistent for RSI-cellularity index value measured in the peri-enhancing zone (HR 3.6, 95 % CI 1.0-12.3, P = 0.041). No statistically significant differences were noted between RSI-cellularity index, FA, nor MD and MGMT promoter methylation.
CONCLUSION: RSI-cellularity index may be used as prognostic biomarker to improve risk stratification in patients with glioblastoma.
引用
- Latysheva A, Geier OM, Hope TR, et al. Diagnostic utility of Restriction Spectrum Imaging in the characterization of the peritumoral brain zone in glioblastoma: Analysis of overall and progression-free survival. Eur J Radiol. 2020. PMID: 33002815. doi:10.1016/j.ejrad.2020.109289
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。